Nephrology franchise further enhanced by agreement with TJ Biopharma to acquire exclusive rights to felzartamab in the Greater China region, potentially one of the largest patient populations globally for IgAN Press Release Cambridge, Mass. – April 29, 2026 Biogen reports strong first quarter 2026 results First quarter 2026 total revenue of $2.5 billion, increased 2% year-over-year; GAAP diluted EPS of $2.15, increased 31% year-over-year; Non-GAAP diluted EPS of $3.57, increased 18% year-over-year Growth pr ...